Zentalis Pharmaceuticals, Inc.

Analysis for Ticker: ZNTL

Zentalis Pharmaceuticals, Inc. is a company that pretends to hunt for cancer cures while operating as a machine that turns investor money into zero-revenue dust. This San Diego company is trying to build molecules like azenosertib for ovarian cancer, but the real story is their bank account. They have never sold a single product, yet they have managed to lose more than 1,19$ billion in a perfect loop of money moving from shareholders to clinical vendors and executives. Think of it like a business that spends millions of dollars on shiny machines but never sells anything; the only way it keeps going is by tricking people into buying new pieces of paper called shares. The math is a disaster because the money they burn every month is guaranteed to leave them with zero dollars by late 2027.